New publication : Mitochondrial morphodynamics alteration induced by influenza virus infection as a new antiviral strategy

Published on 19/02/2021

Together with the team of Etienne Morel, ENYO Pharma continues the antiviral exploration of its molecule targeting the NEET proteins, in the context of influenza virus. In this new article, we demonstrate that MITO-C exerts a membrane signature that strictly counteracts the signature applied by influenza virus infection on the mitochondria and on endoplasmic reticulum-mitochondria contact sites. Consequently, MITO-C potentiates Interferon expression and inhibits viral replication. Publication here

Read next in 'Latest news'

• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH
• New publication : An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters
• Swiss NASH Foundation sponsorship
• ENYO Pharma in the Top 50 of the EIC ScalingUp List